[go: up one dir, main page]

IT8249719A0 - 2-/4-/(4,4-dialchil-2,6-piperidindi on-1-il)-butil/1-piperazinil/pirimi dine ad attivita' ansiolitica selettiva, procedimento per la loro preparazione e preparati farmaceutici che le contengono - Google Patents

2-/4-/(4,4-dialchil-2,6-piperidindi on-1-il)-butil/1-piperazinil/pirimi dine ad attivita' ansiolitica selettiva, procedimento per la loro preparazione e preparati farmaceutici che le contengono

Info

Publication number
IT8249719A0
IT8249719A0 IT8249719A IT4971982A IT8249719A0 IT 8249719 A0 IT8249719 A0 IT 8249719A0 IT 8249719 A IT8249719 A IT 8249719A IT 4971982 A IT4971982 A IT 4971982A IT 8249719 A0 IT8249719 A0 IT 8249719A0
Authority
IT
Italy
Prior art keywords
piperidindi
piperazinil
pirimi
dine
dialkyl
Prior art date
Application number
IT8249719A
Other languages
English (en)
Other versions
IT1158039B (it
Inventor
Davis L Temple
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of IT8249719A0 publication Critical patent/IT8249719A0/it
Application granted granted Critical
Publication of IT1158039B publication Critical patent/IT1158039B/it

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86Oxygen atoms
    • C07D211/88Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56One oxygen atom and one sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
IT49719/82A 1981-12-28 1982-12-22 2-/4-/(4,4-dialchil-2,6-piperidindion-1-il)-butil/1-piperazinil/pirimidine ad attivita' ansiolitica selettiva, procedimento per la loro preparazione e preparati farmaceutici che le contengono IT1158039B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/334,688 US4423049A (en) 1981-12-28 1981-12-28 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines

Publications (2)

Publication Number Publication Date
IT8249719A0 true IT8249719A0 (it) 1982-12-22
IT1158039B IT1158039B (it) 1987-02-18

Family

ID=23308351

Family Applications (1)

Application Number Title Priority Date Filing Date
IT49719/82A IT1158039B (it) 1981-12-28 1982-12-22 2-/4-/(4,4-dialchil-2,6-piperidindion-1-il)-butil/1-piperazinil/pirimidine ad attivita' ansiolitica selettiva, procedimento per la loro preparazione e preparati farmaceutici che le contengono

Country Status (26)

Country Link
US (1) US4423049A (it)
JP (2) JPS58118582A (it)
KR (1) KR870001045B1 (it)
AT (1) AT382373B (it)
AU (1) AU555797B2 (it)
BE (1) BE895504A (it)
CA (1) CA1244426A (it)
CH (1) CH656383A5 (it)
CY (1) CY1379A (it)
DE (1) DE3248160C2 (it)
DK (1) DK162389C (it)
ES (2) ES518510A0 (it)
FI (1) FI70891C (it)
FR (1) FR2518993B1 (it)
GB (1) GB2114122B (it)
GR (1) GR77045B (it)
HK (1) HK5288A (it)
IE (1) IE54619B1 (it)
IT (1) IT1158039B (it)
KE (1) KE3709A (it)
LU (1) LU84561A1 (it)
NL (1) NL193283C (it)
PT (1) PT76036B (it)
SE (1) SE453088B (it)
SG (1) SG29787G (it)
ZA (1) ZA828549B (it)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423049A (en) * 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
US4581357A (en) * 1983-02-07 1986-04-08 Mead Johnson & Company Antipsychotic 5-fluoro-pyrimidin-2-yl piperazine compound
US5187276A (en) * 1983-06-18 1993-02-16 Troponwerke Gmbh & Co. Kg. 2-pyrimidinyl-1-piperazine derivatives
DE3321969A1 (de) * 1983-06-18 1984-12-20 Troponwerke GmbH & Co KG, 5000 Köln 2-pyrimidinyl-1-piperazin-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4668687A (en) * 1984-07-23 1987-05-26 Bristol-Myers Company Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones
CA1250291A (en) * 1984-07-23 1989-02-21 Bristol-Myers Company Psychogeriatric 1-(2-pyrimidinyl)-piperazinyl derivatives of 1-pyrrolidin-2-ones
NL8601494A (nl) * 1985-06-22 1987-01-16 Sandoz Ag Thiazolen, hun bereiding en farmaceutische preparaten die ze bevatten.
US4826843A (en) * 1985-07-08 1989-05-02 Bristol-Myers Cerebral function enhancing diazinylpiperidine derivatives
NZ216720A (en) * 1985-07-08 1990-09-26 Bristol Myers Co Diazinylpiperidine derivatives and pharmaceutical compositions
US4777254A (en) * 1986-12-02 1988-10-11 American Home Products Corp. Cyclic imides as H1 -antagonists
US4771053A (en) * 1987-03-02 1988-09-13 Bristol-Myers Company Method for alleviation of primary depressive disorders
US4782060A (en) * 1987-07-29 1988-11-01 Bristol-Myers Company Gepirone for alleviation of panic disorders
US4880930A (en) * 1987-11-30 1989-11-14 New James S Psychotropic acyclic amide derivatives
US5001130A (en) * 1988-02-18 1991-03-19 Bristol-Myers Company Psychotropic heterobicycloalkylpiperazine derivatives
US5116970A (en) * 1988-02-18 1992-05-26 New James S Psychotropic heterobicycloalkylpiperazine derivatives: 2. fused pyridazinones
US4780466A (en) * 1988-03-17 1988-10-25 Hoechst-Roussel Pharmaceuticals, Inc. Arylpiperazinylalkoxy derivatives of cyclic imides
US5242911A (en) * 1988-06-17 1993-09-07 Pfizer Inc. Bridged bicyclic imides as anxiolytics and antidepressants
US5077295A (en) * 1988-09-16 1991-12-31 Pfizer Inc. Antipsychoic 4-(4-(3-benzisothiazolyl)-1-piperazinyl)buytl bridged bicycle imides
FR2654934B1 (fr) * 1989-11-29 1994-09-30 Midy Spa Utilisation de derive [4-(2-pyrimidinyl)-1-piperazinyl] butyliques pour la preparation de medicaments destines a combattre les troubles de la motricite intestinale.
US5098904A (en) * 1990-06-27 1992-03-24 Bristol-Myers Squibb Company Cerebral function enhancing pyrimidinyl derivatives
AU9164591A (en) * 1990-12-14 1992-07-08 New York University Functional interactions between glial s-100b and central nervous system serotonergic neurons
DE4135551A1 (de) * 1991-08-31 1993-03-04 Schering Ag Verwendung von antagonisten oder partiellen agonisten am 5-ht1a-rezeptor zur behandlung und praevention von kognitiven stoerungen
US5824680A (en) * 1991-08-31 1998-10-20 Bayer Aktiengesellschaft Ipsapirone for the treatment of alzheimer's disease by improving memory
GB9223153D0 (en) * 1992-11-05 1992-12-16 Wyeth John & Brother Ltd Piperazine derivatives
FR2701260B1 (fr) * 1993-02-05 1995-05-05 Esteve Labor Dr Dérivés de 2-[4-(4-azolylbutyl)-1-pipérazinyl]-5-hydroxypyrimidine, leur préparation et leur application en tant que médicaments.
US5338738A (en) * 1993-04-19 1994-08-16 Bristol-Myers Squibb Company Cerebral function enhancers: acyclic amide derivatives of pyrimidinylpiperidines
FR2705098B1 (fr) * 1993-05-10 1995-08-04 Esteve Labor Dr Procédé de préparation de 2-{4-[4-(chloro-1-pyrazolyl)butyl]1-pipérazinyl}pyrimidine (Lesopitron) .
HU217129B (hu) * 1993-07-16 1999-11-29 EGIS Gyógyszergyár Rt. Eljárás nagy tisztaságú buspiron gyógyászati hatóanyag előállítására
US5538985A (en) * 1994-01-27 1996-07-23 Mitsui Toatsu Chemicals, Inc. Pyrrolidinone derivatives
US5521313A (en) * 1994-05-05 1996-05-28 Bristol-Myers Squibb Company Process for preparing certain azapirones
CA2146593A1 (en) * 1994-05-05 1995-11-06 Jack Melton Large-scale process for azapirone synthesis
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
US6312717B1 (en) 1998-07-07 2001-11-06 Bristol-Myers Squibb Company Method for treatment of anxiety and depression
WO2000006163A1 (en) * 1998-07-30 2000-02-10 Bristol-Myers Squibb Company Improved method for treatment of sleep-related respiratory disorders
US6566361B2 (en) 1999-06-30 2003-05-20 Laboratories, Upsa Azapirone pain treatment
CN100367965C (zh) * 1999-12-20 2008-02-13 法布瑞-克雷默制药有限公司 吉吡隆代谢物在制备改善哺乳动物不良心理状态的组合物上的应用
US6534507B1 (en) * 1999-12-20 2003-03-18 Fabre-Kramer Pharmaceuticals, Inc. Methods for treating psychological disorders using bioactive metabolites of gepirone
KR20020068404A (ko) * 2000-01-19 2002-08-27 악조 노벨 엔.브이. 미르타자핀을 포함하는, 우울증 및 관련 장애 치료용 약물조합물
WO2002016347A1 (en) * 2000-08-22 2002-02-28 Akzo Nobel N.V. Active metabolite of gepirone
ES2292636T3 (es) * 2000-11-29 2008-03-16 Eli Lilly And Company 1-(2-m-metanosulfanomidofeniletil)-4-(m-trifluorometilfenil)piper.
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
SG145701A1 (en) * 2003-07-30 2008-09-29 Xenon Pharmaceuticals Inc Piperazine derivatives and their use as therapeutic agents
CA2547283C (en) * 2003-11-26 2010-11-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
AU2004324868B2 (en) * 2004-11-05 2010-04-29 Fabre Kramer Holdings Inc High-dosage extended-release formulation of gepirone
US20060099267A1 (en) * 2004-11-05 2006-05-11 Fabre-Kramer Pharmaceuticals, Inc. High-dosage extended-release formulation of gepirone
EP2159226B1 (de) * 2007-03-29 2016-08-31 Joint-stock Company "Obninsk Chemical Pharmaceutical Company" Antihistamin- und antiallergienmittel sowie verfahren zu seiner herstellung
WO2011030139A1 (en) * 2009-09-11 2011-03-17 Astrazeneca Ab 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
IT201900000657A1 (it) 2019-01-16 2020-07-16 Procos Spa Processo per la sintesi di gepirone
GB202014736D0 (en) * 2020-09-18 2020-11-04 Imperial College Innovations Ltd Novel compounds and their use in therapy
CN119409681A (zh) * 2024-03-28 2025-02-11 北京华素制药股份有限公司 一种盐酸丁螺环酮的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3398151A (en) * 1966-02-01 1968-08-20 Mead Johnson & Co Azaspirodecanediones and azaspiroundecanediones
BE759371A (fr) * 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
US3976776A (en) * 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4182763A (en) * 1978-05-22 1980-01-08 Mead Johnson & Company Buspirone anti-anxiety method
DK251079A (da) 1978-06-20 1979-12-21 Synthelabo Fremgangsmaade til fremstilling af phenylpiperazinderivater
US4423049A (en) * 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines

Also Published As

Publication number Publication date
CY1379A (en) 1987-08-07
IE823067L (en) 1983-06-28
FI70891B (fi) 1986-07-18
ES8506696A1 (es) 1985-08-01
HK5288A (en) 1988-01-29
NL193283C (nl) 1999-05-06
DK162389B (da) 1991-10-21
ES8405786A1 (es) 1984-06-16
ES524945A0 (es) 1985-08-01
DE3248160C2 (de) 1993-12-09
SE453088B (sv) 1988-01-11
DE3248160A1 (de) 1983-07-07
JPS58118582A (ja) 1983-07-14
PT76036B (en) 1985-12-16
SE8207425D0 (sv) 1982-12-27
NL193283B (nl) 1999-01-04
BE895504A (fr) 1983-06-28
LU84561A1 (fr) 1983-09-08
CA1244426A (en) 1988-11-08
GR77045B (it) 1984-09-04
PT76036A (en) 1983-01-01
DK162389C (da) 1992-03-09
AT382373B (de) 1987-02-25
AU9108382A (en) 1983-07-07
AU555797B2 (en) 1986-10-09
US4423049A (en) 1983-12-27
KR840002827A (ko) 1984-07-21
GB2114122A (en) 1983-08-17
SG29787G (en) 1987-07-17
CH656383A5 (de) 1986-06-30
KR870001045B1 (ko) 1987-05-26
FI824442L (fi) 1983-06-29
GB2114122B (en) 1985-11-27
NL8204970A (nl) 1983-07-18
SE8207425L (sv) 1983-08-12
ES518510A0 (es) 1984-06-16
IE54619B1 (en) 1989-12-20
JPH0368875B2 (it) 1991-10-30
FI70891C (fi) 1986-10-27
FI824442A0 (fi) 1982-12-23
FR2518993A1 (fr) 1983-07-01
ZA828549B (en) 1983-09-28
JPH06293753A (ja) 1994-10-21
KE3709A (en) 1987-04-16
IT1158039B (it) 1987-02-18
DK573182A (da) 1983-06-29
FR2518993B1 (fr) 1986-09-05
ATA469882A (de) 1986-07-15

Similar Documents

Publication Publication Date Title
IT8249719A0 (it) 2-/4-/(4,4-dialchil-2,6-piperidindi on-1-il)-butil/1-piperazinil/pirimi dine ad attivita' ansiolitica selettiva, procedimento per la loro preparazione e preparati farmaceutici che le contengono
IT8467767A1 (it) Preparati farmaceutici ad attività antimicrobica e procedimento per la loro preparazione.
IT8467445A1 (it) Composizione e preparato per la somministrazione di medicamenti per via cutanea.
IT1213379B (it) Tiazolo [4,5-c]chinoline, procedimento per la loro preparazione e composizioni farmaceutiche che le contengono.
DE3261497D1 (en) Substituted n-(4-indolyl-piperidino-alkyl) benzimidazolones, processes for their preparation and their use as pharmaceutical preparations
IT8249720A0 (it) 2-/4-/4,4-dialchil-2,6-piperidinadion-1-il)butil/-1-piperazinil/piri dine ad attivita' antipsicotica relativo procedimento di preparazione e preparati farmaceutici che le con tengono
IT8324035A0 (it) Cefem composti ad attivita'farmaceutica e procedimenti per laloro preparazione.
DK159652C (da) Cholecalciferolderivater, disse derivater til brug som terapeutisk aktive substanser, fremgangsmaade til fremstilling deraf samt farmaceutisk praeparat baseret paa disse cholecalciferolderivater
DK354485A (da) 3-substituerede l-aminoalkyl-lh-indol-forbindelser, fremgangsmaader til fremstilling deraf og mellemprodukter til anvendelse derved samt farmaceutiske praeparater
FI853228A7 (fi) Uudet -butyrolaktaamit, niiden farmaseuttisesti aktiiviset koostumukset, menetelmät niiden valmistamiseksi ja niiden käyttö lääkeaineina.
FI831619A7 (fi) 2(1H)-pyridinoni-johdannaiset, niiden valmistus ja niitä sisältävät farmaseuttiset valmisteet.
IT8249771A0 (it) Derivati di cicloesanone aventi attivita' diserbante, e procedimento per la loro preparazione
IT1168389B (it) Derivati di alcandioli con attivita' ipolipidemizzante,metodi per la loro preparazione e composizioni farmaceutiche che li contengono
IT1168163B (it) Composto ad attivita' antiulcera, procedimento per la sua preparazione e composizioni farmaceutiche relative
FI853368A7 (fi) Uusia pseudo-oligosakkarideja, joilla on -glukosidaasia estävä vaikutus, menetelmä niiden valmistamiseksi, niiden käyttö ja farmaseuttisia valmisteita.
IT8322045A0 (it) Per la loro preparazione e oligosaccaridi eterogenei relative composizioni complessabili ed alfa -idosani ad farmaceutiche. attivita' terapeutica, procedimento
IT8121298A0 (it) Nitroimidazoli ad attivita'tricomonacida, procedimento per laloro preparazione e relative composizioni farmaceutiche.
IT8320468A0 (it) Nuovi composti ad attivita'antiinfiammatoria, procedimento per la loro preparazione e composizioni farmaceutiche che licontengono.
ES8800139A2 (es) Mejoras introducidas en el objeto de la patente principal por un procedimiento para la preparacion de derivados de urea.
IT1185513B (it) Procedimento per l'ottenimento di preparati farmaceutici con effetto ritardato
IT8567216A0 (it) Composti pteridinici relativi procedimenti di preparazione e preparati farmaceutici che li contengono
FI822980A7 (fi) Furanokromonijohdannaisia, menetelmiä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia valmisteita.
IT8026232A0 (it) Composizioni farmaceutiche. derivato dell'alfa-mercapto propionilglicina ad attivita'terapeutica, procedimento per lasua preparazione e relative
IT8421431A1 (it) "nuovi preparati farmaceutici con azione antitumorale"
IT8520150A0 (it) Nuovi derivati ad attivita'terapeutica, procedimento per laloro preparazione e relative composizioni farmaceutiche.

Legal Events

Date Code Title Description
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19961227